Intuitive SurgicalWide moat

ISRG — overall economic moat

Investment snapshot
Wide moat→ Holding steadyConfidenceHighValuationFair
Strongest advantageA per-procedure toll enforced in the instrument's own firmware
Greatest threatMore than half of the procedures are elective, and American insurance decides how many happen
Key metricDa Vinci procedure growth (18% in 2025; guided 13.5-15.5% for 2026)
Verdict: The moat is intact and the growth rate is not. Recurring revenue reached 84%, utilisation rose and gross margin improved - and the shares fell 39% because two points of US procedure growth turned out to belong to a subsidy expiry rather than to the company.
📈 ISRG valuation, revenue & earnings — P/E, P/S, revenue, EPS →

Intuitive Surgical sells surgical robots, and that is the least important thing about it. In 2025 it placed 1,721 da Vinci systems and booked $2,473.7 million of systems revenue1 — a quarter of the company. The other three quarters came from what happens after the machine is bolted down.

Intuitive Surgical revenue, 2025 ($M)Instruments and accessories — 60%Systems — 25%Service — 16%Total $10,064.7M. $874.3M of the systems band is operating-lease income, so 84% of the whole is recurring.
The robot is a quarter of the company. Everything else arrives per procedure or per year, from machines already installed.

The filing gives the number without ceremony. Recurring revenue — instruments and accessories, service, and lease payments — was $8,465.3 million of $10,064.7 million, or 84%2. Instruments and accessories alone were $6,018.9 million, service $1,572.1 million, operating leases $874.3 million. Roughly 3.30 million da Vinci and Ion procedures were performed on Intuitive equipment during the year3, which works out at about $1,825 of consumables per procedure4. The robot is a toll booth that hospitals pay about $1.6 million to install.

And the toll is enforced in silicon. Describing its instruments, the 10-K says: "A programmed memory chip inside each instrument performs several functions that help determine how the da Vinci surgical system and instruments work together. In addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures"5. Expiry is built into the blade, by design, and the company says so on the page.

The scale behind that is large and still compounding. An installed base of about 11,710 da Vinci systems and 1,096 Ion systems at 30 June 2026, up 12% and 21% on the year6. Da Vinci procedures grew 18% in 2025 to about 3,153,000 and Ion procedures 51% to about 144,100. Utilisation — procedures per system per year — rose 3%, so the base is not merely getting bigger, it is getting busier. Gross margin was 66.0% in 2025 and 67.8% in the June 2026 quarter; operating income $2,945.5 million, net income attributable to Intuitive $2,856.0 million, diluted earnings $7.87 a share7. There is no debt at all, and $8.63 billion of cash and investments.

What 2026 revealed is that none of this determines the growth rate. Buried in the seasonality discussion of the 10-K is the sentence that explains the year: "More than half of da Vinci procedures performed are for benign conditions"8. Benign means elective. Elective means deferrable. And when the enhanced premium subsidies under the Affordable Care Act expired, patients began deferring — first in hernia repairs and cholecystectomies, the categories management identifies as the deferrable ones. United States da Vinci procedure growth went from 14% in the first quarter of 2026 to 12% in the second9. Management cut full-year guidance to 13.5% to 15.5% and said it expected to land near the midpoint10, against 18% actually delivered in 202511.

The market's response was violent. The shares were $398.58 on 23 September 2026, against a 52-week high of $603.88 — about 34% lower12. Market value has gone from roughly $207 billion at the end of 2025 to about $141 billion, so something like $66 billion has been removed from a company whose revenue grew 19% in the June quarter and whose operating income grew 31%. It now trades at about 45 times trailing earnings and 12.8 times sales, having spent five consecutive years between 66 and 80 times13.

Two things are worth holding in mind together. The moat is genuinely wide: 84% recurring revenue, more than 5,600 granted patents14, a base of surgeons whose training is specific to this console, and a razor-and-blade arrangement with the expiry date in the razor. And the moat does not control demand. Intuitive can decide what a procedure costs and how well it goes; it cannot decide whether an American with a hernia has insurance this year.

The number that tests the whole thesis is not revenue and not the installed base. It is worldwide da Vinci procedure growth, guided to about 14.5% for 2026 after 18% in 2025 and 17% in 2024. That series is what the recurring revenue is a function of, and the last two prints have gone the wrong way for a reason that has nothing to do with robots. Its three revenue lines are taken in turn in The Revenue Lines.

The number that tests this moat
Reported
Revenue, and where it comes from
$10,064.7M — 84% of it recurring, 25% systems

Systems are a quarter of the company and everything anyone writes about it. Instruments and accessories ($6,018.9M) plus service ($1,572.1M) plus lease income is $8,465.3M that arrives whether or not a hospital buys anything. Watch the recurring share: it has risen every year, and it is the reason a bad capital year is not a bad year.

Source: Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 ↗
Moat scorecardHow ratings work →
Switching costs9/10
Network effects7/10
Pricing power8/10
Hard to replicate8/10
Disruption resistance6/10
Overall durability8/10

Switching costs are the highest here that are held by someone the company does not employ - a surgeon's motor skill, learned in residency and used three million times a year. Pricing power is real and Intuitive has just chosen to give some of it back, raising permitted instrument uses from 2027. Disruption resistance is the weak score: fourteen named rivals cleared the same 510(k) route, and more than half of the procedures can be deferred or medicated away.

Dig deeper
DIG DEEPER 01
The Revenue Lines
Three lines that grow together because the robots and the contracts exist to sell the instruments.
DIG DEEPER 02
The Moat
A toll collected per operation and enforced in firmware — which decides what share of a procedure Intuitive captures, and nothing at all about how…
DIG DEEPER 03
Competitors
Twenty-five years without a serious rival, and then two arrived in eight months — plus one that is a drug.
DIG DEEPER 04
Major Clients
No customer above ten percent, and one payer decision per country that moves everything at once.
✦ Future bets — beyond today's moat
✦ FUTURE BET 01
The Future Bets
No moonshot — a feature Europe has not certified, a single-port system in its early stages, a digital layer with no price, and four governments…
⚠ Threats to the moat
⚠ THREAT 01
The Growth Rate Is Set in Washington
The widest moat in medical devices, and its growth rate is set by whether an American with a hernia has insurance this year.
⚠ THREAT 02
A Ministry Decides How Big China Is
559 surgical robots for the whole country, allocated by tender, shared with every competitor.
◆ What the market may be missing
◆ THE VARIANT VIEW
What the Market Isn't Pricing In
The moat is intact, the growth rate is lower, and the company has just chosen to trade toll for volume — which nobody is modelling.
◆ THE VARIANT VIEW
Inside the Latest Quarter (Q2 2026)
Revenue up 19%, operating income up 31%, margin guidance raised, and the shares fell 12% the next day.
References
  1. ReportedIn 2025 it placed 1,721 da Vinci systems and booked $2,473.7 million of systems revenue — a quarter of the company.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedRecurring revenue — instruments and accessories, service, and lease payments — was $8,465.3 million of $10,064.7 million, or 84%.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, results of operations (instruments and accessories $6,018.9M, systems $2,473.7M, service $1,572.1M, recurring revenue $8,465.3M, gross margin 66.0%, operating income $2,945.5M, average selling price, lease revenue recognition, and the discussion of procedure categories) — FY2025 · publ. February 3, 2026 · source ↗
  3. Moat Explorer calcRoughly 3.30 million da Vinci and Ion procedures were performed on Intuitive equipment during the year, which works out at about $1,825 of consumables per procedure.
    Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
  4. Moat Explorer calcRoughly 3.30 million da Vinci and Ion procedures were performed on Intuitive equipment during the year, which works out at about $1,825 of consumables per procedure.
    Moat Explorer calculation - arithmetic on figures reported in Intuitive's Form 10-K and Form 10-Q: instruments and accessories of $6,018.9M over 3,153,000 da Vinci plus 144,100 Ion procedures ($1,825 a procedure), service revenue of $1,572.1M over the installed base (about $134,000 a system), variable lease revenue of $531M over 1,810 usage-based systems (about $293,000), procedures over the average installed base (about 300 a system), each revenue line as a share of the $10,064.7M total, and US general surgery as a share of US procedures — FY2025 · publ. September 2026 · source ↗
  5. ReportedIn addition, the chip generally will not allow the instrument to be used for more than the prescribed number of procedures".
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  6. ReportedAn installed base of about 11,710 da Vinci systems and 1,096 Ion systems at 30 June 2026, up 12% and 21% on the year.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  7. ReportedGross margin was 66.0% in 2025 and 67.8% in the June 2026 quarter; operating income $2,945.5 million, net income attributable to Intuitive $2,856.0 million, diluted earnings $7.87 a share.
    Intuitive Surgical Form 10-Q, quarter ended June 30, 2026 (installed base 11,710 da Vinci systems up 12%, 468 placements of which 246 were da Vinci 5, the operating-lease share, the distributor acquisitions in Italy, Spain and Portugal, cash and investments of $8.63 billion, and the factors expected to affect future placements) — Q2 2026 and the first six months · publ. July 21, 2026 · source ↗
  8. ReportedBuried in the seasonality discussion of the 10-K is the sentence that explains the year: "More than half of da Vinci procedures performed are for benign conditions".
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  9. ReportedUnited States da Vinci procedure growth went from 14% in the first quarter of 2026 to 12% in the second.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  10. ReportedManagement cut full-year guidance to 13.5% to 15.5% and said it expected to land near the midpoint, against 18% actually delivered in 2025.
    Intuitive Surgical Q2 2026 earnings call - the Extended Use Program raising permitted uses on selected EndoWrist instruments from the first half of 2027, US da Vinci procedure growth of 12% against 14% attributed to the expiry of enhanced Affordable Care Act premium subsidies, full-year guidance of 13.5% to 15.5% nearer the midpoint, gross-margin guidance raised to 68-69%, and Japanese placements of 25 against 15 — Q2 2026 · publ. July 16, 2026 · source ↗
  11. ReportedManagement cut full-year guidance to 13.5% to 15.5% and said it expected to land near the midpoint, against 18% actually delivered in 2025.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  12. ReportedThe shares were $398.58 on 23 September 2026, against a 52-week high of $603.88 — about 34% lower.
    Intuitive Surgical (NASDAQ: ISRG) market data, 23 September 2026 - $398.58 a share, market capitalisation $140.81 billion on 353.28 million shares, P/E 46.11, forward P/E 35.59; 52-week high $603.88 (companiesmarketcap: $142.84 billion) — September 2026 · publ. 2026-09-23 · source ↗
  13. ReportedIt now trades at about 45 times trailing earnings and 12.8 times sales, having spent five consecutive years between 66 and 80 times.
    Intuitive Surgical (NASDAQ: ISRG) market data, 23 September 2026 - $398.58 a share, market capitalisation $140.81 billion on 353.28 million shares, P/E 46.11, forward P/E 35.59; 52-week high $603.88 (companiesmarketcap: $142.84 billion) — September 2026 · publ. 2026-09-23 · source ↗
  14. ReportedThe moat is genuinely wide: 84% recurring revenue, more than 5,600 granted patents, a base of surgeons whose training is specific to this console, and a razor-and-blade arrangement with the expiry date in the razor.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026